We have written about the promise of gene therapy to correct genetic disease many times. An exciting development happened ...
CRISPR technology could one day create “designer babies, ” raising major ethical and social inequality concerns.
Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...
In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...
Durable reprogramming of human T cells may now be possible thanks to a new technique based on the CRISPRoff and CRISPRon methodology. Researchers from the Arc Institute, Gladstone Institutes, and the ...
Biotech firm Metagenomi said it is using artificial intelligence chips from Amazon.com's cloud computing unit to power some ...
OPEN TO DEBATE: As modern warfare becomes increasingly automated and reliant on artificial intelligence, the question of who, or what, should have ultimate control over lethal decision-making systems ...
Researchers at Integra Therapeutics, in collaboration with the Pompeu Fabra University (UPF) Department of Medicine and Life Sciences (MELIS) and the Center for Genomic Regulation (CRG), have designed ...
University College London's National Amyloidosis Center leads a multinational team reporting that a single infusion of an in vivo gene-editing therapy (nexiguran ziclumeran) produced rapid, deep, and ...
Is it the invasion of the genome snatchers? Just in case the idea of aliens walking around in human skin suits wasn’t frightening enough. An outlandish study asserts that aliens might have abducted us ...
A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...
A few months after launching its lead gene therapy into the clinic, Arbor Biotechnologies has found a European partner to come along for the ride. Italian pharma Chiesi is fertilizing Arbor’s rare ...